Search results for "Administration"

showing 10 items of 5106 documents

Gonadotropin Secretion in Eugonadotropic Human Males and Postmenopausal Females Under Long Term Application of a Potent Analog of Gonadotropin-Releas…

1978

Long-acting analogs are of special interest in long-term treatment with gonadotropin-releasing hormone (GnRH). However, inhibitory effects of agonist analogs on gonadotropin secretion or on reproductive processes have been observed in rats as well as in human males. Since these inhibitory effects seem to be dose-related, we checked the findings for d-Leu 6 -des-Gly 10 -GnRH-ethylamide within the dose range proposed by us for treatment. In six eugonadotropic human males, a significant decrease of luteinizing hormone and follicle-stimulating hormone responsiveness to a standard dose of GnRH and significant decrease of testosterone basal secretion were observed after 2 and 4weeks of subcutaneo…

AdultMaleAgonistendocrine systemmedicine.medical_specialtyTime Factorsmedicine.drug_classInjections SubcutaneousGonadotropin-releasing hormoneHuman MalesBiologyGonadotropin-Releasing HormoneBasal (phylogenetics)Internal medicinemedicineHumansTestosteroneAdministration IntranasalTestosteroneObstetrics and GynecologyLuteinizing HormoneGonadotropin secretionEndocrinologyReproductive MedicineFemaleFollicle Stimulating HormoneMenopauseLuteinizing hormonePituitary Hormone-Releasing Hormoneshormones hormone substitutes and hormone antagonistsHormoneFertility and Sterility
researchProduct

Busulfan systemic exposure after oral administration of extemporeanously prepared high-dose busulfan capsules.

2009

Purpose. The aim of the study was to analyze patients’ busulfan (BU) exposure after oral administration of extemporeanously prepared BU capsules prior to blood stem cell transplantation. Methods. Patients were treated with 1 mg/kg body weight BU administered orally every 6h on each of 4 consecutive days prior to blood stem cell transplantation. Each BU dose was administered in 1 gelatine capsule to be swallowed and containing the individually calculated dose of pure BU active substance. Blood samples were obtained from 6 adult patients 0, 30, 60, 90, 120, 180, 240, 300, and 360 min after the 1st, 5th, and 13th BU dose, frozen and analyzed subsequently by using a HPLC assay with UV detectio…

AdultMaleAlkylating AgentsTransplantation ConditioningDrug CompoundingAdministration OralCapsulesPharmacologyHplc assayPharmacokineticsOral administrationMedicineHumansPharmacology (medical)BusulfanCyclophosphamideChromatography High Pressure LiquidPeripheral Blood Stem Cell Transplantationmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryCapsuleMiddle AgedTransplantationOncologyTherapeutic drug monitoringConcomitantArea Under CurveDrug Therapy CombinationFemaleSpectrophotometry UltravioletDrug MonitoringbusinessBusulfanmedicine.drugJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
researchProduct

Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angio-oedema.

2008

Background:  Skin swellings are the most frequent symptoms in hereditary angio-oedema (HAE) arising out of C1-inhibitor (C1-INH) deficiency. They may be painful and impact daily activities of patients. Detailed clinical data concerning the treatment of skin swellings by C1-INH concentrate have not been reported yet. Methods:  From 1976 through 2007, a total of 2104 skin-swelling attacks in 47 patients with HAE were treated with the C1-INH concentrate. Time to relief and duration of the swellings were documented during personal interviews using standardized questionnaires. The results were compared with 9046 untreated skin swellings in the same patients. Results:  The first clinical sign of …

AdultMaleAllergymedicine.medical_specialtyHereditary angio-oedemaAdolescentImmunologyC1-inhibitorImmunopathologyImmunology and AllergyMedicineHumansIn patientProspective StudiesChildAgedRetrospective StudiesSkinbiologybusiness.industryAngioedemas HereditaryDrug administrationMiddle Agedmedicine.diseaseTrunkSurgerybiology.proteinFemaleLaryngeal oedemabusinessComplement C1 Inhibitor ProteinAllergy
researchProduct

Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study.

2014

Abstract Introduction Epistaxis is the most frequent manifestation in hereditary hemorrhagic telangiectasia, in which no optimal treatment exists. It can lead to severe anemia and reduced quality of life. Positive effects of tranexamic acid, an antifibrinolytic drug, have been reported on epistaxis related to this disorder. We sought to evaluate the efficacy of treating nosebleeds in hereditary hemorrhagic telangiectasia with tranexamic acid. Materials and Methods In a randomized, double-blind, placebo controlled, cross-over phase IIIB study, 1 gram of tranexamic acid or placebo was given orally 3 times daily for 3 months for a total of 6 months. Results 22 patients were included in the int…

AdultMaleAntifibrinolyticTime Factorsmedicine.drug_classMedizinAdministration OralPlaceboDrug Administration ScheduleDouble blindQuality of lifeDouble-Blind MethodGermanymedicineHumansTelangiectasiaAgedDiminutionCross-Over Studiesbusiness.industryHematologyMiddle AgedAntifibrinolytic AgentsClinical trialEpistaxisTreatment OutcomeTranexamic AcidAnesthesiaFemaleTelangiectasia Hereditary Hemorrhagicmedicine.symptombusinessTranexamic acidmedicine.drugThrombosis research
researchProduct

CEA and CA19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-ho…

2001

Summary Background There have been contradictory reports on the benefit of CEA and CA 19-9 measurements in patients with metastatic colorectal cancer using palliative chemotherapy. The object of this study was to examine the diagnostic accuracy of monitoring of palliative chemotherapy by means of CEA and CA19-9. Patients and methods The tumour markers CEA and CA 19-9 were subjected to serial measurement in patients with metastatic colorectal cancer (n = 90) using palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-FU with FA and were compared with objective response according to WHO criteria. 85 patients could be evaluated. 43 patients (51%) initially had elevated…

AdultMaleAntimetabolites Antineoplasticmedicine.medical_specialtyPalliative careCA-19-9 AntigenColorectal cancerLeucovorinSensitivity and SpecificityGastroenterologyDrug Administration ScheduleFolinic acidCarcinoembryonic antigenRecurrenceInternal medicinemedicineHumansInfusions IntravenousAgedTumor markerbiologybusiness.industryPalliative CareHematologyMiddle Agedmedicine.diseaseChemotherapy regimenCarcinoembryonic AntigenSurgeryOncologyFluorouracilbiology.proteinFemaleCA19-9FluorouracilColorectal Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

A Bayesian Method for Predicting 5‐Fluorouracil Pharmacokinetic Parameters Following Short‐Term Infusion in Patients With Colorectal Cancer

2003

Abstract The objective of this study was to develop a population pharmacokinetic model and validate it using a Bayesian approach for predicting, a priori and a posteriori , the individual volume of distribution ( V d ) and clearance ( Cl ) of 5‐fluorouracil (5‐FU) given as short‐term intravenous infusion in weekly and multiple doses. Forty‐four patients were divided in group A (5‐FU weekly doses) including 27 patients with nonmetastatic colorectal adenocarcinoma treated with 450 mg/m 2 of 5‐FU, 1 day per week for 48 doses, plus oral levamisol (50 mg/8 h) for 3 days, every 15 days and group B (5‐FU multiple doses) including 17 patients with metastatic colorectal adenocarcinoma, receiving 5‐F…

AdultMaleAntimetabolites Antineoplasticmedicine.medical_specialtyPopulationUrologyPharmaceutical ScienceRenal functionModels BiologicalDrug Administration ScheduleFolinic acidPharmacokineticsInternal medicineBlood plasmamedicineHumansInfusions IntravenouseducationAgedBody surface areaVolume of distributioneducation.field_of_studybusiness.industryBayes TheoremMiddle AgedNONMEMEndocrinologyArea Under CurveFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drugJournal of Pharmaceutical Sciences
researchProduct

A Highly Decreased Binding of Cyclic Adenosine Monophosphate to Protein Kinase A in Erythrocyte Membranes is Specific for Active Psoriasis

2002

A cyclic adenosine monophosphate binding abnormality in psoriatic erythrocytes that could be corrected by retinoid treatment has been reported. It was tested whether this binding abnormality is specific for psoriasis and the effects of treatment were compared with etretinate, cyclosporine A, or anthralin on 2-(3)H-8-N(3)-cyclic adenosine monophosphate binding to the regulatory subunit of protein kinase A in erythrocyte membranes. One hundred and fifteen individuals were evaluated, including: (i) 34 healthy persons; (ii) 15 patients with nonatopic inflammatory skin diseases (eczema, erythroderma, tinea, Grover's disease, erysipelas, urticaria); (iii) eight with other dermatoses mediated by i…

AdultMaleAzidesmedicine.medical_specialtyAdolescentmedicine.drug_classAdministration TopicalAnti-Inflammatory AgentsErythrodermaEtretinateDermatologySeverity of Illness IndexBiochemistryRetinoidschemistry.chemical_compoundPsoriasis Area and Severity IndexKeratolytic AgentsPsoriasis Area and Severity IndexPsoriasisInternal medicineCyclic AMPmedicineHumansPsoriasisCyclic adenosine monophosphateRetinoidMolecular BiologydermatitisAgedErythema nodosumbusiness.industryErythrocyte MembraneAffinity LabelsCell BiologyAtopic dermatitisAnthralinMiddle Agedmedicine.diseaseCyclic AMP-Dependent Protein KinasesEndocrinologychemistryEtretinateCyclosporineFemaleDermatologic Agentsbusinesscyclosporine AProtein Bindingmedicine.drugJournal of Investigative Dermatology
researchProduct

Lorcainide. I. Saturable presystemic elimination.

1979

AdultMaleBenzeneacetamidesAdministration OralPharmacologyHepatic VeinsIn Vitro TechniquesPulmonary ArteryLorcainidePiperidinesMedicineHumansPharmacology (medical)Aorta AbdominalAortaAgedPharmacologybusiness.industryArrhythmias CardiacBlood ProteinsMiddle AgedBloodInjections IntravenousAcetanilidesFemalebusinessAnti-Arrhythmia Agentsmedicine.drugProtein BindingClinical pharmacology and therapeutics
researchProduct

The Influence of Chitosan on the Oral Bioavailability of Acyclovir-a Comparative Bioavailability Study in Humans

2015

Purpose The effects of chitosan hydrochloride on the oral absorption of acyclovir in humans were studied to confirm the absorption enhancing effects reported for in vitro and rat studies, respectively. Methods A controlled, open-label, randomized, 3-phase study was conducted in 12 healthy human volunteers. Zovirax 200 mg dispersible tablets co-administered with doses of 400 and 1000 mg chitosan HCl were compared with Zovirax only. Results The expected increased absorption of acyclovir was not observed. On the contrary, mean area under the plasma concentration-time curve (AUC0-12 h) and maximal plasma concentration (Cmax) decreased following concomitant chitosan intake (1402 versus 1017 and …

AdultMaleBioavailability StudyAcyclovirAdministration OralBiological AvailabilityPharmaceutical Science02 engineering and technologyAbsorption (skin)PharmacologyAntiviral Agents030226 pharmacology & pharmacyHealthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]Chitosan03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacokineticsbiopharmaceutics classification systemHumansMedicinePharmacology (medical)Chromatography High Pressure LiquidPharmacologyChitosanDrug Carriersbusiness.industryOrganic Chemistry021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystembiowaiverHealthy Volunteers3. Good healthBioavailabilitychemistryexcipient interactionsData Interpretation StatisticalMolecular MedicineFemaleChitosan hydrochloridebioavailability0210 nano-technologybusinesspharmacokineticsResearch PaperBiotechnologyBiological availabilityPharmaceutical Research
researchProduct

Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain d…

2011

Abstract Context Cancer patients receiving high doses of opioids as background medication are challenging, and it would be useful clinically to know whether a rapid-onset opioid (ROO) for breakthrough cancer pain (BTcP) may be started at a dose proportional to the background opioid dose. Objectives The aim of this study was to assess the efficacy and safety of the fentanyl buccal tablet (FBT) in doses proportional to the opioid dose administered for background analgesia in a sample of patients with BTcP who were receiving high doses of opioids. Methods Twelve patients who were receiving opioids for background analgesia at doses equivalent to more than 500 mg of oral morphine and had adequat…

AdultMaleBreakthrough PainContext (language use)Settore MED/42 - Igiene Generale E ApplicataFentanylNeoplasmsHumansMedicineAdverse effectGeneral NursingAgedPain MeasurementDose-Response Relationship Drugbusiness.industryBreakthrough PainAdministration BuccalCancerclinical trialBuccal administrationMiddle Agedmedicine.diseaseFentanyl buccal tabletbreakthrough pain cancer patientAnalgesics OpioidFentanylTreatment OutcomeAnesthesiology and Pain MedicineOpioidAnesthesiaFemaleNeurology (clinical)businessCancer painmedicine.drug
researchProduct